Hemophiliacs with inhibitors: therapeutic options.
D000328:Adult; D000906:Antibodies / Q000032:analysis; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D005164:Factor IX / Q000009:adverse effects / Q000627:therapeutic use*; D015949:Factor IXa; D005169:Factor VIII / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications / Q000191:economics / Q000628:therapy*; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male
D000906:Antibodies; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII; D005164:Factor IX; D015949:Factor IXa